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Introduction
Congenital generalized lipodystrophy (CGL), also known
as Berardinelli-Seip congenital lipodystrophy (BSCL), was
first described by this author in 1954 (1). It is a rare genetic
disorder that has only been reported in 300 patients (2). Its
prevalence in the United States is 1 per 12 million (3). Two
subtypes of BSCL, designated as type 1 and type 2, have
been defined.  Magré et al (4) identified a locus linked to this
disease on chromosome 11q13, and labeled it BSCL2, which
corresponds to type 2 BSCL. This type is characterized by a
generalized lipoatrophy, not restricted to the subcutaneous area
(5), that is associated with significant insulin resistance and
its sequelae, namely, diabetes, hyperinsulinemia, 
dyslipidemia, hepatic steatosis, acanthosis nigricans, 
polycystic ovaries, and hypertension (6,7,8). There may be
additional pathology such as cardiomyopathy, developmental
delay, bone cysts, nephromegaly and nephropathy
(9,10,11,12,13,14). The aim of this paper was to present this
illustrative BSCL patient and underline that CGL should be
considered in the differential diagnosis of non-obese
patients with diabetes and insulin resistance.
Case Report
A 14-year-old girl, offspring of a family who recently
moved from Yemen to the United States, presented with
symptoms of abdominal pain, polyuria and polydipsia, which
had started a few weeks ago. The severity of the abdominal
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had increased in the past 2 days. The patient was reported
to have had a protuberant abdomen since birth, which had
shown no change in the recent past.  She had frequent
voidings that worsened over the last few weeks. She had a
very good appetite. Ingestion of fluids was reported as 
adequate. The patient was born full term and had had no
perinatal problems, but was developmentally delayed
(talked and walked at age 4 years).  At 8 years of age, she
was diagnosed to have diabetes mellitus (DM) in Jordan by
routine blood tests that showed a high blood sugar.
Hypertension was diagnosed a few years later. The parents
were told that the prognosis was poor. No treatment was
offered for DM or hypertension. Breast development and
pubic hair were noticed at age 9 years and axillary hair and
body odor - at age 11 years. She had increased facial and
body hair, but the age at which this was noticed was not
clear. The patient had not yet started her menstrual periods.
She had a history of poor dental hygiene and poor vision.
The family history revealed a consanguineous relationship
(distant cousins) between the father and mother who were
otherwise healthy.  The patient has three sisters and one
brother who are all reported to have no medical problems.
There is no family history of congenital or metabolic 
diseases. A review of the symptomatology is listed in Table 1,
and the findings on physical examination are given in Table
2. Vital signs at presentation were: pulse: 98/min, blood
pressure: 144/84 mmHg, respiration: 20 /min, afebrile. She
weighed 40.3 kg (5th percentile for age, -1.7 SD) and her
height was 144 cm (under the 3rd percentile, -2.25 SDS),
her body mass index(BMI) was 19.4 kg /m2 (0.00 SD). The
pertinent features were: absence of subcutaneous fat in
the extremities, face, trunk and hands; prominent muscles;
looking much older than her stated age; dysmorphic 
features; developmental delay; hepatosplenomegaly; 
poor vision; enophthalmus; and arthropathy. There was no
evidence of retinopathy. Laboratory data are listed in 
Table 3. Her serum glucose was 393 mg/dL and there 
was no metabolic acidosis. Given the history of fever 
and hepatosplenomegaly, screening for human 
immunodeficiency virus, Hepatitis A, B, C, and tuberculin
test were done, and were all negative. Imaging studies
demonstrated striking organomegaly involving the liver,
spleen, and kidneys. Stool impaction was evident on X-ray.
Ultrasound of the abdomen showed hepatomegaly,
enlargement of the main portal vein, numerous splenic
varices, and splenomegaly indicating a mild degree of 
portal hypertension. Radiograms showed mottled bones.
Echocardiogram revealed aortic insufficiency and left 
ventricular hypertrophy.  Chromosomal analysis specifically
for mutation of 11q13 and 9q34 is not yet completed. 
The clinical features and laboratory data of this patient
suggested a diagnosis of congenital lipodystrophy, and
more specifically of BSCL2. She was started on an insulin
regimen of 1 unit/kg/day and increased up to 6 units/kg/day
(300 units daily). Her present insulin regimen 
includes glargine (100 units) at bedtime and aspart 
(40-60 units) before each meal. Given the risks of liver 
toxicity associated with metformin, metformin was started
at 250 mg once a day and gradually increased to 500 mg
twice a day. Liver function tests were monitored every 6
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Table 1. Reported symptoms in the history of the patient
System Review 
General Fatigue
Fever occurring every 2-4 weeks 
(detected by touching the skin), hot flashes
Eye-Nose-Throat Blurry vision, poor visual acuity, tooth caries, 
multiple missing teeth
Respiratory/Chest Difficulty in breathing
Cardiovascular None
Gastrointestinal Encopresis, chronic abdominal pain
Genitourinary Amenorrhea
Musculoskeletal Daily pain in hand and feet. 6 digits in the 
right upper and the right lower extremities
Skin  Darkening of the skin on the neck
Neurologic Headaches, memory loss, developmental 
delay
Psychiatric Depression, tendency to be frustrated 
Endocrine Polyuria, polydipsia, polyphagia 
Table 2. Physical findings of the patient
System Physical Finding
General Dysmorphic, progeric in appearance, Lack of  
subcutaneous fat in maxilla, legs, arms, and 
trunk. Prominent calf muscles.
Eye-Nose-Throat Enophthalmus, prominent forehead, eyebrows
and mandible. Big ears.  Several teeth miss
ing, caries in many teeth.  Hair on the side of 
the face  and on the chin.
Chest /Respiratory Tanner II stage breasts
Cardiovascular III/VI holosystolic murmur
Gastrointestinal Hepatosplenomegaly, umbilical hernia
Genitourinary Tanner V stage pubic hair, clitoris prominent
Musculoskeletal Polydactily in the right extremity.  High arched
soles.  Bony prominences along the upper 
extremity . PIP joints, contracture of PIP and 
DIP joints
Skin  Increased pigmentation around the umbilicus,
neck, and knuckles of hands and feet.
Neurological Brisk patellar tendon reflexes
Psychiatric Introvert personality weeks. Even with combined insulin and metformin therapy,
her blood sugar has remained in the 200-500mg/dL 
range. Her hemoglobin A1c (HbA1c), which was 12.2% at
diagnosis, had improved to 10.6% over a 6-month period.
She is encouraged to do more physical activity. She was
also started on ergocalciferol and calcium for vitamin D 
deficiency. The carious teeth were extracted. For persistent
proteinuria and nephromegaly, a kidney biopsy was done
that showed IgA nephropathy. She was placed 
on angiotensin-converting enzyme inhibitor for persistent
proteinuria and hypertension. Her blood pressure has 
normalized on antihypertensive medication. Portal 
hypertension has been monitored closely as these patients
are at risk for esophageal varices. 
Discussion
BSCL is a condition characterized by absence of 
functional adipocytes to store fat.  As a result of this defect,
fat is stored in tissues like muscle and liver. Hepatomegaly
and muscle hypertrophy ensue due to excessive deposition
of circulating triglycerides (5). Insulin resistance can
become severe by the second decade of life, making the
diabetes difficult to control with conventional therapy (3).
Pathogenesis of the generalized lipodystrophy is secondary
to adipocyte deficiency (6). The result is a distinct phenotypic
appearance of generalized lipoatrophy that is exacerbated
by the severity of the diabetes and subsequent insulin
resistance. Major diagnostic criteria of CGL include trunk,
limb, and facial lipoatrophy. Acromegaloid features are 
characteristic and consist of prognathism, enlarged
hands/feet, macrogenitosomia, which are all thought to 
be a result of insulin cross-reacting with insulin-like growth
factor-1 (IGF-1) receptors (5). Minor criteria include 
hypertrophic cardiomyopathy, psychomotor or mental 
retardation, hypertrichosis, hirsutism, and bone cysts with
premature closure of the epiphyseal plates (3). Renal 
disorders may include nephromegaly and nephropathy (5).
Our patient had most of the above features, except for
bone cyst and cardiomyopathy. Her echocardiogram
showed aortic regurgitation and left ventricular hypertrophy.
Her left ventricular hypertrophy may be secondary to 
long-standing poorly controlled hypertension. Other 
features unique to our patient include polydactyly in the
right upper and lower extremities as well as arthropathy
with contractures at proximal interphalangeal (PIP) and 
distal interphalangeal (DIP) joints. The arthropathy may be
secondary to poorly controlled long-standing diabetes or
other undiagnosed etiology.
Infants with BSCL usually present with findings secondary
to lipoatrophy, failure to thrive or gigantism, developmental
delay, and dysmorphism (3). Alternate diagnoses to be 
considered in the differential diagnosis are progeria,
Russell’s diencephalic syndrome, leprechaunism and 
lysosomal storage disorders (3). 
Patients with CGL in the under-10 age group commonly
present with accelerated growth, cognitive impairment, and
abnormal fat distribution. By the second decade, symptoms
of weight loss, polyuria, polydipsia, and polyphagia ensue
and the diagnosis of diabetes is ultimately made. Our
patient was diagnosed with diabetes at 8 years of age.
Differential diagnosis in this age group is less extensive and
includes: Dunningham lipodystrophy, a syndrome, 
which spares Bichat’s pads in the face; progeria, which is
characterized by premature senility, sclerotic skin, joint 
contractures and alopecia; and Rabson-Medenhall 
syndrome, the prominent features of which are short
stature, protuberant abdomen,  abnormalities of teeth and
nails, and  pineal hyperplasia, with no organomegaly (3).
Laboratory evaluation usually reflects insulin resistance,
with impaired glucose tolerance, dyslipidemia and 
hyperinsulinemia. Our patient had normal fasting insulin 
levels, mildly elevated C-peptide, elevated triglyceride and
low HDL cholesterol levels. Other features of insulin 
resistance in our patient were acanthosis nigricans and 
hirsutism.  Hepatic steatosis will commonly result in a mild
transaminitis as triglycerides deposit into the liver 
178
Roth T et al.
Congenital Lipodystrophy
Table 3. Laboratory data of the patient
Test Results Normal ranges
Vitamin D3, 25 OH (ng/mL) 13.6 32-100
Vitamin D3, 1,25 (OH)2 (pg/mL) 14.8 15.9-55.6
Calcium (mg/dL) 9.8  8.9-10.7
Phosphorus (mg/dL) 3  3.5-5
Alkaline phosphatase (units/L) 152 0-170
Prealbumin (mg/dL)  <5 17-42  
Parathormone intact pg/mL 19.3 12-65
C-Peptide (ng/mL) 3.5 0.4-3.3
Hemoglobin A1c (%) 12.2 4-6
Triglycerides (mg/dL) 385 0-150
LDL (mg/dL) 69 0-110
HDL (mg/dL) 31 40-150
Insulin, ulU/mL 6.8 0-29.1
Glutamic acid decarboxylase  (U/mL) <0.1 0-1.5
Estradiol (pg/mL 29 20-500
Karyotype 46 XX -
17 Alpha OH progesterone (ng/dL) 58 0-240
Testosterone, free (pg/mL) 3.6 1.1-6.3
Testosterone, total (ng/dL) 30 10-55
Cortisol, random (ug/dL) 8.9 7-25
ACTH (pg/mL) 38 6-48
TSH (ng/mL) 4.0 0.4-5.5
Leptin (ng/ml) <0.5 1.1-27.5secondary to a paucity of generalized fat tissue (5). As a
consequence of near-total loss of body fat, serum levels of
adipocytokines such as leptin and adiponectin are low (15).
DNA testing can help differentiate subtypes of BSCL.
Mutation of band 13 (called locus BSCL2) on the long arm
of chromosome 11 prevents the coding of the enzyme
seipin. This mutation is found in patients with congenital
lipodystropy Type 2 (5). Conversely, a mutation on band 
34 (called locus BSCL1) of the long arm of chromosome 
9 inhibits the production of the enzyme 1-acylglycerol-
3-phosphate O-acyltransferase 2 (AGPAT2) (4,5). This is
indicative of congenital lipodystrophy Type 1. In contrast to
type 1, unique features of type 2 are greater prevalence of 
cognitive dysfunction, cardiomyopathy, less lytic bone
lesions and involvement of both metabolically active 
adipose tissue (found in most subcutaneous tissue sites, in
intraabdominal, intrathoracic sites and in the bone marrow)
and mechanical adipose tissue (located in the palms, soles
of the exremities, under the scalp, in the retroorbital and
periarticular regions) (5,6). In Type 1, only metabolically
active adipose tissue is involved. Our patient showed 
developmental delay, left ventricular hypertrophy and
involvement of both metabolically active (less 
subcutaneous tissue, less intraabdominal fat revealed by
abdominal CT scan) and mechanical adipose tissue (less fat
in the palms and soles, enophthalmus). Management of
lipodystrophy centers on controlling the diabetes, 
improving the insulin resistance, and reducing the 
triglyceride levels. Patients with CGL, as exemplified in this
case report, are quite resistant to insulin therapy. Insulin
doses as high as 1000 units daily may be required to 
control blood glucose levels (16) and even these doses may
not suffice. Metformin has been shown to have some
effect in helping patients reduce their appetite and improve
symptoms of polycystic ovarian syndrome (PCOS) 
and hepatic steatosis (17). Our patient showed mild
improvement in HbA1c on a combined regimen of insulin
and metformin. Care should be taken in monitoring hepatic
functions closely, as metformin is associated with 
hepatotoxicity.  The most promising   treatment for patients
with CGL is recombinant leptin. This medication appears to
improve insulin sensitivity, decrease triglyceride levels, and
help control energy homeostasis. This results in less food
intake, and lower fasting blood glucose levels as well as
lower HbA1c levels (18). Some reports show 
normoglycemia on leptin therapy even after other 
discontinuing hypoglycemic agents (19).We are planning to
enroll our patient in a leptin trial.
In summary, CGL is an uncommon genetic disorder.
The patient described in this case report unfortunately went
undiagnosed for many years. Maldistribution of body fat led
to the pathological changes in the liver, kidneys, and 
muscles.  Ultimately, diabetes and subsequent insulin
resistance developed. With the exception of cardiomyopathy
and lytic bone lesions, this patient meets all the major and
minor criteria for the diagnosis of congenital generalized
lipodystrophy type 2 (BSCL2). 
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